Bayer Healthcare LLC

Bayer Pharmaceuticals Corporation

Scott Wilhelm

Jacques P Dumas

Gaetan H Ladouceur

Chengzhi Zhang

Barton W Phillips

Wendy Lee

Qian Zhao

Benjamin Jones

Zhi Chen

Dongping Fan

Michael J Burke

William Johnston Scott

Bernd Riedl

Stephen Boyer

Mark Lynch

Richard W Gedrich

Ian Taylor

The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.

Diaryl ureas for diseases mediated by PDGFR

The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST (4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide).

Treatment of cancers with acquired resistance to kit inhibitors

A compound of Formula (I): salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.

Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of HER-2, EGFR, VEGF, u-PA, p-PAI-1, and soluble forms thereof, as biomarkers for cancer, especially for subjects treated with sorafenib.

Methods for prognosis and monitoring cancer therapy

This invention relates to a novel fused tricyclic heterocycle of the formula and its use for the treatment of hyper-proliferative disorders.

Fused tricyclic heterocycles useful for treating hyper-proliferative disorders

This invention relates to a novel fused tricyclic heterocycle of the formula (Ia, Ib) and its use for the treatment of hyper-proliferative disorders 

Growing community of inventors

Orange, CT, United States of America

Scott Wilhelm